EORTC research presented at ESMO 2026
22 Oct 2026
EORTC will showcase a strong portfolio of oral and poster presentations at the ESMO Congress 2026, taking place in Madrid, Spain, from 23-27 October 2026. Oral presentations will feature results from clinical and translational research studies, while a broad poster programme will highlight ongoing and planned trials, methodological research, patient involvement initiatives, and quality of life research, reflecting the breadth of EORTC’s multidisciplinary cancer research programme.
EORTC ABSTRACTS |
|
ORAL PRESENTATIONS |
|
| INFORMED CONSENT MATERIALS THROUGH THE EYES OF PATIENTS: A QUALITATIVE ANALYSIS OF EORTC PATIENT REVIEWS Iryna Shakhnenko, Belgium |
Saturday, 24 October 2026, 15:47 – 15:52 Type: Rapid Oral Session Location: Seville Auditorium – NCC Abstract number: 3324RO |
| COMPARABLE SWALLOWING FUNCTION AT 12 MONTHS BUT DIVERGENT TOXICITY PROFILES WITH TOS VERSUS DO-IMRT IN EARLY-STAGE OROPHARYNGEAL, SUPRAGLOTTIC AND HYPOPHARYNGEAL CARCINOMA: PRIMARY RESULTS OF THE PHASE III EORTC 1420 BEST-OF TRIAL Christian Simon, Switzerland |
Sunday, 25 October 2026, 09:28 – 09:38 Type: Proffered Paper Session Location: Madrid Auditorium – Hall 4 Abstract number: 1535O |
| FINAL ANALYSIS OF ADJUVANT PEMBROLIZUMAB (PEMBRO) IN RESECTED EARLY-STAGE NON-SMALL-CELL LUNG CANCER (NSCLC): PHASE 3 PEARLS/KEYNOTE-091 STUDY Mary O’Brien, United Kingdom |
Monday, 26 October 2026, 15:43 – 15:53 Type: Proffered Paper Session Location: Alicante Auditorium – Hall 6 Abstract number: 2511O |
POSTERS |
|
| IMPACT OF ENZALUTAMIDE-RELATED DRUG–DRUG INTERACTIONS ON ADVERSE EVENTS IN THE EORTC 1333GUCG PEACE-3 TRIAL Mehdi Bsilat, Belgium |
Friday, 23 October 2026, 15:15 – 16:00 Type: Poster Session Location: Lorem ipsum Abstract number: 2245P |
| ADJUVANT TEBENTAFUSP (IMCGP100) VERSUS OBSERVATION IN HLA-A*02:01 POSITIVE PATIENTS FOLLOWING DEFINITIVE TREATMENT OF HIGH-RISK UVEAL MELANOMA: AN EORTC RANDOMIZED PHASE III STUDY Paul Nathan, United Kingdom |
Saturday, 24 October 2026, 12:00 – 12:45 Type: Trial in Progress Poster Location: Lorem ipsum Abstract number: 2139TiP |
| ≥4 POSITIVE NODES IDENTIFY A POPULATION ENRICHED FOR ctDNA-GUIDED ADJUVANT TREATMENT ESCALATION IN ER+/HER2− EARLY BREAST CANCER Teck Long King, Belgium |
Saturday, 24 October 2026, 12:00 – 12:45 Type: Poster Session Location: Lorem ipsum Abstract number: 583P |
| ANALYSIS AND REPORTING OF PFS IN CONTEMPORARY PHASE 2-3 TRIALS IN SOLID ONCOLOGY: A SYSTEMATIC REVIEW Annemiek Van Ommen-Nijhof, Netherlands |
Sunday, 25 October 2026, 12:00 – 12:45 Type: Poster Session Location: Lorem ipsum Abstract number: 3332P |
| CURRENT PRACTICE CONSIDERATIONS FOR BRAIN METASTASES IN GASTROESOPHAGEAL CANCER PATIENTS: AN INTERNATIONAL EORTC SURVEY Hannah C. Puhr, Austria |
Lorem ipsum Type: E-Poster Location: Lorem ipsum Abstract number: 749eP |
| COVERAGE OF TREATMENT-RELATED TOXICITIES BY EORTC QLQ-C30 AND QLQ-H&N43 IN HEAD AND NECK CANCER Myrto Moutafi, Greece |
Lorem ipsum Type: E-Poster Location: Lorem ipsum Abstract number: 1622eP |
| DIAGNOSIS, TREATMENT AND FOLLOW-UP PRACTICES FOR LOCALLY ADVANCED NASOPHARYNGEAL CANCER (NPC) IN NON-ENDEMIC REGIONS: AN EORTC LED SURVEY Alvina Vadassery, Belgium |
Lorem ipsum Type: E-Poster Location: Lorem ipsum Abstract number: 1623eP |
Related News
EORTC Quality of Life Group at ISOQOL 2026
15 Oct 2026
Pink October 2026: Advancing breast cancer research, together
7 Oct 2026
EORTC presents new results in neuro-oncology at EANO
28 Sep 2026
In Memoriam: Neil Aaronson, founding member of the EORTC Quality of Life Group
7 Sep 2026
New EORTC perspective calls for patient preferences to become a standard part of cancer trials for older adults
4 Sep 2026
New EORTC questionnaire sets a global standard for measuring quality of life in cancer survivors
25 Aug 2026
EORTC calls for a balanced and feasible European Health Data Space (EHDS)
8 Jul 2026
Professor Benjamin Besse becomes President of EORTC
26 Jun 2026
CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer
24 Jun 2026
EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials
24 Jun 2026
